Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

• DOI: 10.1007/s13555-024-01135-x
• Publication Date: 2024-03-21T03:01:48Z
• Authors: Luigi Gargiulo; Luciano Ibba; Piergiorgio Malagoli; Anna G. Burroni; Andrea Chiricozzi; Paolo Dapavo; Silvia M. Ferrucci; Massimo Gola; Maddalena Napolitano; Michela Ortoncelli; Maria T. Rossi; Claudio Sciarrone; Antonio Costanzo; Alessandra Narcisi
• Keywords: Clinical Practice; Delphi Method; Delphi

Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval patients with AD after being evaluated in several clinical trials. However, a few concerns raised regarding their long-term safety management these drugs real-world practice. this article we described results Delphi consensus aimed at describing knowledge on JAKi focusing, providing recommendations dermatologists daily practice use drugs. Twelve Italian reviewed most recent literature efficacy profiles proposed 24 statements. Agreement was reached statements focusing three main topics: (1) place therapy moderate-to-severe AD; (2) effectiveness JAK different phenotypes; (3) approaches to treated The panel all Given wide practice, it is crucial establish specific follow-up each patient's phenotype order achieve best possible outcome minimize potential adverse events.